Russell Investments Group
CRBP icon

Russell Investments Group’s Corbus Pharmaceuticals CRBP Stock Holding History

Russell Investments Group’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.5K Buy
1,760
+1,314
+295% +$12.4K ﹤0.01% 3840
2026
Q1 		$4.19K Hold
446
– – ﹤0.01% 3921
2025
Q4 		$3.63K Hold
446
– – ﹤0.01% 3947
2025
Q3 		$5.64K Buy
446
+320
+254% +$3.04K ﹤0.01% 3885
2025
Q2 		$869 Buy
126
+97
+334% +$705 ﹤0.01% 3686
2025
Q1 		$154 Buy
29
+9
+45% +$79 ﹤0.01% 3740
2024
Q4 		$236 Sell
20
-56
-74% -$939 ﹤0.01% 3651
2024
Q3 		$1.57K Buy
+76
New +$3.89K ﹤0.01% 3420
2021
Q1 		– Sell
-470
Closed -$17K – 3114
2020
Q4 		$17K Sell
470
-9,741
-95% -$364K ﹤0.01% 2989
2020
Q3 		$551K Sell
10,211
-153
-1% -$27.7K ﹤0.01% 2348
2020
Q2 		$2.6M Buy
10,364
+1,894
+22% +$383K 0.01% 1486
2020
Q1 		$1.33M Buy
8,470
+1,205
+17% +$204K ﹤0.01% 1696
2019
Q4 		$1.19M Hold
7,265
– – ﹤0.01% 2018
2019
Q3 		$1.06M Buy
+7,265
New +$1.27M ﹤0.01% 1977
2017
Q1 		– Sell
-3,312
Closed -$854K – 3001
2016
Q4 		$854K Buy
+3,312
New +$759K ﹤0.01% 2264

Other funds holding CRBP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PAP
Persistent Asset Partners Hong Kong $335M AUM 275.57% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Russell Investments Group's CRBP Position: Q2 2026 in Review

Russell Investments Group increased its Corbus Pharmaceuticals (CRBP) stake by 295% in Q2 2026, buying an estimated $12.4K and bringing the position to 1,760 shares worth $16.5K. The position accounts for ﹤0.01% of the portfolio, ranked #3840.

Russell Investments Group first reported a position in CRBP in Q4 2016 and has held it in 15 quarters since. The position peaked at $2.6M in Q2 2020. 32 funds tracked by Wall St. Rank hold CRBP as of Q2 2026.

  • Russell Investments Group held 1,760 shares of Corbus Pharmaceuticals worth $16.5K as of Q2 2026.
  • Russell Investments Group bought 1,314 Corbus Pharmaceuticals shares in Q2 2026, an estimated $12.4K.
  • Corbus Pharmaceuticals made up ﹤0.01% of Russell Investments Group's portfolio in Q2 2026, its #3840 holding.
  • Russell Investments Group first reported a position in Corbus Pharmaceuticals in Q4 2016 and has held it in 15 quarters since.
  • Russell Investments Group's Corbus Pharmaceuticals position peaked at $2.6M in Q2 2020.
  • 32 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q2 2026.

Based on Russell Investments Group's 13F filing for Q2 2026, filed 6 Aug 2026.